

# PGS and prevention of recurrent miscarriage: facts and fiction



**Tanya Milachich, PhD**

**ESHRE Campus symposium**

**Effects of ART and endometriosis on pregnancy  
outcome**

**SIGs Early Pregnancy and Endometriosis and Endometrial  
disorders**

**27 - 28 January 2017, Sofia, Bulgaria**

# Disclosure


Conflicts of interest: none



Recurrent pregnancy loss (RPL), also referred to as recurrent miscarriage or habitual abortion, is historically defined as 3 consecutive pregnancy losses prior to 20 weeks from the last menstrual period.



Ford and Shust, Rev. Obstet. and Gynecol. 2009



# RPL

Second World Congress of RPL, Cannes, France 19-22 Jan, 2017



## Reasons:

Endocrine aspects, BMI, Vit D3, Prevalence of Vitamin D;

Imm.processes: at Feto-maternal interphase, Decidual Th1/Th2&NK1/NK2 phenotyping, Anti-P Allo-Antibodies, APLA Syndrome, Elevated peripheral NK cells, Hereditary Thrombophilia;

Mol.and Chrom. level: Trombophilia gene mutation, Deficiency of Placental Copy Number Variations, Trophoblast Growth Pathways, RNA-Seq Analysis of Chorionic Villi, Chromosomal Abnormalities e.g. Balanced Structural Chromosomal Anomalies;

Infections: Gardnerella Vaginalis, toxoplasmosis, rubella, CMV, endometritis;


Role of Oxidative Stress, Anatomical Causes, Cervical Incompetence;

**Treatment:** G-CSF Treatment, Lymphocyte Immunization, Anti-Oxidants Treatment, Endoscopic Septectomy, HS, Aspirin, Medformin, Low Molecular Weight Heparin;

**Methods:** Time-lapse, Endometrial biopsy, Embryo morphology, Role of Sperm Selection (IMSI), PGS;

**Other side effects of RPL:** Depression and Anxiety

# Implantation and ART




- Hydrosalpinx
- Mock ET
- Endometrium
- Uterus anomaly
- Endometriosis
- BMI
- Immunological factors
- Genetic factors
- Life style

NIHCE Guidance, 2013

# The pregnancy loss iceberg

An overview of the outcome of spontaneous human conceptions




**75% of embryos are lost before delivery**

**Most of those losses are in the period BEFORE implantation**

Larsen et al. BMC Medicine 2013 11:154

- *Less than **5% of oocytes**, collected after controlled ovarian stimulation, can lead to a pregnancy and then to the birth of a child.*



Stoop D et al. Reproductive potential of a metaphase II oocyte retrieved after ovarian stimulation: an analysis of 23 354 ICSI cycles. Hum Reprod 2012

# How many frozen eggs does everyone need?

## How many MII are needed to achieve a pregnancy?

Outcomes compared between patients 30-36 and 37-39

**TABLE 2**

The outcome comparison between young age versus advanced age patients' oocytes after vitrification.

	Young age group 30–36 y (n = 11)	Advanced age group 37–39 y (n = 11)	P value
Patient age (mean y ± SD) <sup>a</sup>	32.91 ± 1.97	37.90 ± 0.83	< .0001
Mean basal FSH (mean mIU/mL ± SD)	6.20 ± 2.26	6.20 ± 0.92	NS
Survival rate (%)	80/97 (82.5)	68/89 (76.4)	> .9999
Fertilization rate (%)	68/97 (70.1)	56/89 (62.9)	NS
No. of good-quality embryos on day 3 (%) <sup>a</sup>	54/97 (55.6)	36/89 (40.4)	.3639
No. of embryos transferred (mean ± SD) <sup>b</sup>	24 (2.18 ± 0.6)	29 (2.64 ± 1.0)	NS
No. of clinical pregnancies (%)	7/11 (63.6)	3/11 (27.3)	.3509
No. of implantations (%)	10/24 (41.7)	6/29 (20.7)	< .05
No. of take home babies (%)	6/11 (54.5)	2/11 (18.2)	NS
No. of live births	8	3	.2056
Percentage of oocyte to achieve a live birth (%)	8/97 (8.2)	3/89 (3.3)	NS
			.1827
			.2173

**Nb of oocytes to obtain a live birth**

**N=12**

**N=29**

**How many OPU ?????**


Chang et al., Fertil Steril 2013






## 1.3% of oocytes give a baby

### Example of some results




Pregnancy rate/cycle initiated	23.2%
Pregnancy rate/embryo transfer	41.1%
Fetal heart beat (FHB)/cycle initiated	22.0%
FHB/embryo transfer	39.0%
FHB/embryos transferred	25.9%
Live birth rate (LBR)/cycle initiated	18.0%
Live birth rate/embryo transfer	32.0%

ESHRE PGD consortium meeting, Helsinki 2016




**50-70%**  
**60%-70%**  
**60-70%**  
**70-90% FR**  
**80-85% M2**


Blastocyst (unhatched)



Biopsy (hatched blastocyst)



Still no consensus of which stage to biopsy





Palini et al., 2013; Gianaroli et al., 2014


Cell-free DNA in spent culture media



Galluzzi et al., 2015; Shamonki et al., 2016




### PGS results for a chaotic embryo



## Evolution of PGD for translocations


Fluorescence In Situ Hybridisation (FISH)



PCR-based STR Analysis (Fiorentino et al., 2010)



Array Comparative Genomic Hybridisation (aCGH)  
(Fiorentino et al., 2011)




Next Generation Sequencing (NGS) (Bono et al., 2015)



## NGS performance for <5Mb size fragments

TRANSLOCATION		Chromosome A <sup>a</sup>		Chromosome B <sup>b</sup>		NGS	aCGH
		Centric segment <sup>c</sup>	Translocated segment <sup>c</sup>	Centric segment <sup>c</sup>	Translocated segment <sup>c</sup>		
46,XY,t(3;10)(p13;q26)	b5	125,5	74,0	134,4	1,0	✗	✗
46,XY,t(3;18)(p26;q12)	b5	197,0	2,8	33,7	42,4	✗	✓
46,XY,t(14;15)(q32;q1)	b5	104,6	1,8	39,0	61,3	✗	✗
46,XY,t(2;11)(q37;p10)	b5	239,8	3,2	88,4	46,1	✗	✗



Slides, used with permission of A. Biricik, Laboratorio Genoma

# PGS and prevention of recurrent miscarriage: facts




- There is still risk of miscarriage 16-30% after PGS
- We can not completely avoid the miscarriages
- PGS improve pregnancy rate in those patients
- Combined with AMA there is a very small chance for euploid embryo and for deliver a healthy baby

De Rycke et al., 2015 - ESHRE PGD Data collection XII



## % aneuploidy in embryos according to indication for PGS



Data from 7000 blastocysts tested by array-CGH or NGS

Slide, used with permission of  
A. Biricik, Laboratorio Genoma



# ESHRE PGD Consortium data collection XIII: cycles from January to December 2010 with pregnancy follow-up to October 2011

**Table Vb**

Cycles performed for PGS, data collection XIII.


Indication	AMA	AMA + misc	AMA + + RIF	Rec.misc	RIF	SMF	Prev abn preg	AMA + Rec mis Pre abn Preg	Num Abnor	AMA + Num abno	No indication	Ovum donation	AMA + Ovum donation	Total
Cycles to OR	1083	265	312	415	456	278	44	2	33	1	51	37	2	2979
Number infertile	688	162	297	145	405	245	14	0	25	1	43	36	2	2063
Female age (years)	39	37	40	36	32	37	36	42	36	41	37	43	44	39
ART method														
Delivery rate (% per OR/% per ET)	10/17	15/25	5/8	22/28	16/20	22/26	34/42	0	27/32	0	29/38	16/18	50/50	14/21
Miscarriages	33	6	7	18	19	9	1	0	1	0	2	3	0	99
Miscarriage rate (% per clinical pregn – pregn lost to FU)	23	13	30	16	19	12	6	0	9	0	11	33	0	18
Clinical pregnancies lost to FU	2	3	5	5	14	8	1	0	0	0	0	1	0	39





National Institute for Health and Clinical Excellence (2013). Fertility: Assessment and treatment for people with fertility problems; NICE clinical guideline 156.

Dunson DB, Baird DD, Colombo B (2005). Increased infertility with age in men and women. *Obstet Gynecol.*103(1):51-6.



# Genetic consultation before ART



**Y-microdeletions**  
**Lachapelle**  
**Morris syndrome**  
**Teacher Collins syndrome**



# Genetic counseling / TIME



- Medical history – family members
- Evaluation of severity of the genetic problem
- Evaluation of all risks
- Give a realistic expectations
- Information about all processes, including confirmation of results
- Additional testing if needed
- Discussion of other options – pro and cons
- Inform consent



# Seven reasons to be concerned about the use of the new - PGS



## 1. Do not forget evidence-based medicine

The patients should not be randomized by the number of embryos. Usually, in the new-PGS there are a minimum number of viable blastocysts as a rule to initiate patient randomization.

## 2. An adverse past and an uncertain future

A minimum of 6 to 8 embryos available for biopsy. AMA? DOR?

## 3. The trophectoderm is an area of chromosomal variability

The trophectoderm blastocyst biopsy: The aneuploidy rate can be around 70% in day 3 versus approximately 20%-50% in the blastocyst with significant degree of embryo self-correction.

## 4. Data are missing for several indications as RIF

At the moment, there is no proper RCT was carried out with the PGS-new in populations RIF.

## 5. Indicating PGS-new for infrequent populations

In 2011, 3 RCTs were published about the use of PGS in patients labeled as good prognosis (Staessen et al., 2008; Jansen et al., 2008; Meyer et al., 2009). Back then, they did not find significant differences in *terms of live birth rate* among patients with or without PGS.

The original intent of this study was to improve *IVF pregnancy rates*. As this failed, their original intent was replaced by the listed secondary goal of this study: reduction of twin pregnancies at elective single transfer (Gleicher et al., 2014).

Jose Franco, JBRA, 2015



## 6. Concerns about **extended culture to the blastocyst stage**

- Blastocyst stage in vitro cultures risks: 1- prolonged embryo culture has been related to significant *epigenetic changes* (Loneragan et al., 2003; Calle et al., 2012); 2- blastocyst stage culture are associated with increased *risk of premature delivery* in comparison to embryos transferred on days 2 or 3 (Maheshwari et al., 2013; Dar et al., 2014).

## 7. **Non-maleficence**


- In 2008, ASRM, ESHRE and the British Fertility Society declared that PGS (day 3 biopsy + FISH technique) is *ineffective* in improving IVF pregnancy rates and reducing miscarriage. Seven years later, these societies have not yet settled for or against PGS-new (day 5-6 biopsy + CGH or qPCR or NGS), as well as the Brazilian Society of Assisted Reproduction (SBRA).

Jose Franco, JBRA, 2015

- Mosaics embryos: 55% до 73% [Munne et al., 2006; Bielanska et al, 2002];

## Mosaic embryos can develop into healthy newborns

Clinical outcome	No.
No. of ET	49
No. of embryos transferred	50
No. of + $\beta$ hCG pregnancies	24
No. of biochemical pregnancies	5
No. of early miscarriages	4
No. of ongoing clinical pregnancies per ET	15 (30.6%)
No. of pregnancies went to term	15 (30.6%)
No. of babies born	16




Updated data from: Greco E, Minasi MG and Fiorentino F, *N Engl J Med* 2015; 373:2089-90

Slide, used with permission of A. Biricik, Laboratorio Genoma



# Why are (most of us) chromosomally normal?



Survival of the fittest cell (Robberecht, 2010);

20-30% of de novo unbalanced translocations: postzygotic origin;



# PGS and prevention of recurrent miscarriage: facts and myths



## Facts:

- Many embryos have *'self-correct'* mechanism reaching the blastocyst stage and also after this stage (up to 4%);
- Near 70% of embryos in patient with RM are aneuploid;
- 28% Delivery Rate per ET in young female patients;
- RM – there is 16-18% risk of miscarriage;
- 0% Delivery Rate in patients with RM, when is combined with AMA and previous abnormal pregnancy;

## Myths:

- We can completely avoid the miscarriage risk by using PGS in couples with RM
- There is a high chance for euploid embryos after PGS
- There is a high chance for delivery in AMA cases

Johnson et al., 2010; Baart et al, 2007; Munne et al., 2005; De Rycke et al., 2015 - ESHRE PGD Data collection XII



Still nearly 30% of patients with RM have chance for take-home baby after PGS if there is no issue of AMA





Picture used by Sthepane

Viville

CHAPATTE



## Conclusions:

1. In the future: Are we be able to find the perfect embryo with the fast development of NGS?
2. How many embryos per couple we will need?
3. Is there a perfect human being at all?
4. For now we are capable to chose the less affected embryo among all others?
5. New data shows that mosaic embryos can develop into a healthy newborn in 32% of all cases.
6. Every case must be well discussed and genetically consulted prior and after PGS

*The complexity and the wonder of life....A simple friendship, a sunny day, our life*





## ART team - gynaecologists, embryologists, biologists:

A.Shterev

S.Kyurkchiev

T.Timeva

D.Barov

I.Hadgiiska

PGD Genetic consultants

I.Dimova M.Savova

D.Savova

T.Milachich

B.Petkova

N.Trpchevska

P.Andreeva

L.Valkova

A.Dimcheva

M.Dimitrova

G.Ganeva

I.Antonova

R.Petkova

PGD team Genoma

M.Yunakova

B.Bandreva

F.Florentino

M.Konovalova

P.Penkova

A.Biricik

T.Arabadgi

L.Veleva

A.Nucitelli et al.

R.Milcheva

D.Nikolova

N.Magunska

I.Canov

M.Alexandrov

P.Gavrilov

R.Bilchev

I.Bochev

